Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE
Samir Dalia, MD
Christopher Jurief
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Benjamin Levy, MD
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Heather Wakelee, MD, FASCO
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
Reshma L. Mahtani, DO
Chairperson’s Perspective: Precision in Practice: Advancing EGFR-Altered Metastatic NSCLC Through Guideline-Concordant, Case-Based Learning
Natasha B. Leighl, MD, MMSc
From Risk to Resilience: Best Practices for Improving Outcomes in Early-Stage ER+/HER2- Breast Cancer
Theresa W. Gillespie, PhD, MA, RN, FAAN
Kristi Orbaugh, MSN, RNP, AOCN
Kimberly Podsada, MSN, NP-C
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
Carlos M. de Castro, MD
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Jorge E. Cortes, MD
Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
Mark Socinski, MD
Patrick Forde, M.B.B.Ch.
Karen Reckamp, MS, MD
Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
Ayse Tuba Kendi, MD
A. Oliver Sartor, MD
Loading...
We're glad to see you're enjoying AXISMedEd… but how about a more personalized experience?
Press cancel to remain on AXISMedEd. Press the link below or the continue button to keep going.